Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease

Neurology

Volumn 77, Issue 1, 2011, Pages 39-47

  Ikonomovic, M D ^a,b   Klunk, W E ^a   Abrahamson, E E ^a   Wuu, J ^c   Mathis, C A ^a   Scheff, S W ^d   Mufson, E J ^e   DeKosky, S T ^f  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; CHOLINE ACETYLTRANSFERASE; PITTSBURGH COMPOUND B;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CHOLINERGIC ACTIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; PRIORITY JOURNAL;

EID: 80051520187     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182231419     Document Type: Article

References (39)

1. Buxbaum JD, Oishi M, Chen HI, et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer β/A4 amyloid protein precursor. Proc Natl Acad Sci USA 1992;89:10075-10078.
2. Liskowsky W, Schliebs R. Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favors the amyloidogenic route of processing of amyloid precursor protein. Int J Dev Neurosci 2006;24:149-156. (Pubitemid 43294621)
3. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306-319. (Pubitemid 38269583)
4. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ 42(43). Neuron 1994; 13:45-53.
5. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-7717. (Pubitemid 41208641)
6. Sperling RA, Laviolette PS, O'Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009;63: 178-188.
7. Karas G, Scheltens P, Rombouts S, et al. Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. Neuroradiology 2007;49:967-976. (Pubitemid 350159837)
8. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009; 65:557-568.
9. Wagner AD, Shannon BJ, Kahn I, Buckner RL. Parietal lobe contributions to episodic memory retrieval. Trends Cogn Sci 2005;9:445-453. (Pubitemid 41208254)
10. Cavanna AE, Trimble MR. The precuneus: a review of its functional anatomy and behavioral correlates. Brain 2006; 129:564-583. (Pubitemid 43278220)
11. Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp 2005;26:231-239. (Pubitemid 41759880)
12. Sheline YI, Raichle ME, Snyder AZ, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry 2010;67:584-587.
13. Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 1983;214:170-197. (Pubitemid 13162962)
14. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002;59:198-205. (Pubitemid 34779177)
15. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropath Exp Neurol 1999;58:376-388. (Pubitemid 29187900)
16. Lopez OL, Becker JT, Klunk W, et al. Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology 2000;55:1854-1862. (Pubitemid 32103968)
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944. (Pubitemid 14076461)
18. Petersen RC, Smith GE, Waring SC. Mild cognitive impairment. Arch Neurol 1999;56:303-308.
19. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001;58:397-405. (Pubitemid 32217456)
20. National Institute on Aging and Reagan Institute Working Group on Diagnosis Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of AD. Neurobiol Aging 1997;18:S1-S2.
21. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
22. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82: 239-259.
23. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Postmortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131: 1630-1645. (Pubitemid 351806448)
24. Klunk WE, Lopresti BJ, Ikonomovic MD, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-β in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005;25:10598-10606. (Pubitemid 41681907)
25. DeKosky ST, Scheff SW, Markesbery WR. Laminar organization of cholinergic circuits in human frontal cortex in Alzheimer's disease and aging. Neurology 1985;35:1425-1431. (Pubitemid 15242415)
26. Davis KL, Mohs RC, Marin D, et al. Cholinergic markers in elderly patients with early signs of Alzheimer's disease. JAMA 1999;281:1401-1406. (Pubitemid 29190218)
27. DeKosky ST, Ikonomovic MD, Styren S, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002;51:145-155. (Pubitemid 34111436)
28. Thal DR, Rub U, Orantes M, Braak H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-1800. (Pubitemid 34663580)
29. Mufson EJ, Chen EY, Cochran EJ, Beckett LA, Bennett DA, Kordower JH. Entorhinal cortex β-amyloid load in individuals with mild cognitive impairment. Exp Neurol 1999;158:469-490. (Pubitemid 29382838)
30. Price JL, McKeel DWJ, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009;30: 1026-1036.
31. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452. (Pubitemid 44214969)
32. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456-1465.
33. Kemppainen NM, Aalto S, Wilson IA, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007;68:1603-1606. (Pubitemid 46717985)
34. Pike KE, Savage G, Villemagne VL, et al. β-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007;130:2837-2844. (Pubitemid 350033975)
35. Lue LF, Kuo YM, Roher AE, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999;155:853-862. (Pubitemid 29426831)
36. Rosen RF, Ciliax BJ, Wingo TS, et al. Deficient highaffinity binding of Pittsburgh compound B in a case of Alzheimer's disease. Acta Neuropathol 2010;119:221-233.
37. Cohen AD, Price JC, Weissfeld LA, et al. Basal cerebral metabolism may modulate the cognitive effects of Aβ in mild cognitive impairment: an example of brain reserve. J Neurosci 2009;29:14770-14778.
38. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509-1517.
39. 11 C]-PIB PET imaging. J Alzheimers Dis 2010;21:995-1003.